If you or a loved one have been diagnosed with an aggressive blood cancer, a clinical trial studying the potential of a new targeted treatment could be an option. Continue reading to learn more about an ongoing trial and see if you are eligible to enroll.
enitociclib
How Your Cancer Genetics Can Help You Find Potential Treatment Options
Cancer is caused by changes to specific genes that control how our cells grow and divide. Some cancers are characterized by increased activity of a protein called Positive Transcription Elongation Factor B (P-TEFb). P-TEFb plays a central role in helping cancer cells survive and thrive by increasing levels of specific genes. Enitociclib specifically targets these critical genes. Through this targeted approach, enitociclib induces cancer cell death.
About Enitociclib
- Enitociclib is a selective inhibitor of PTEFb/CDK9 and is expected to show efficacy in tumor indications that overexpress MYC and MCL-1.
- Enitociclib monotherapy has demonstrated an acceptable toxicity profile and preliminary efficacy in Phase 1 studies in advanced cancer.
- The combination (VVIP) targets major cell-death pathways in lymphoid malignancies (BCL-2 and MCL-1) and may overcome chemo-resistance and/or single drug resistance to venetoclax.
Tumor Growth & Progression
Controls Tumor Growth & Progression in Preclinal Studies
Vincerx has partnered with the National Institutes of Health to study enitociclib in combination with venetoclax and prednisone for the treatment of aggressive blood cancers.
For more information on this trial, please visit Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies